S2210 Kickoff Meeting

Join us in Seattle, or virtually, to learn about opening and enrolling to this new phase II prostate cancer trial.

FRIDAY, APRIL 5 • 8 – 9 AM, PT • BECKLER ROOM (302), LEVEL 3

S2210 is enrolling patients with high-risk localized prostate cancer who carry an inherited BRCA1 or BRCA2 pathogenic mutation.

Hypothesis: these patients will benefit from neoadjuvant carboplatin chemotherapy before surgery to remove their prostate cancer. Carboplatin is a DNA-damaging drug that is especially effective against other cancers with BRCA1 or BRCA2 mutations.

An estimated 5% of high-risk patients carry an inherited BRCA1 or BRCA2 mutation, although having a strong family history of cancer (especially breast cancers at an early age, ovarian, pancreas and metastatic prostate cancers) increases the likelihood of being a carrier.

Genetic testing for an inherited BRCA1 or BRCA2 mutation is now clinically indicated for patients with high-risk prostate cancer (NCCN guidelines). So timely workflows will help your site implement guideline-concordant genetic testing and counseling, *and* help you find candidates for S2210.

CHAIRS

Heather H. Cheng, MD, PhD



Daniel W. Lin, MD

Evan Y. Yu, MD

Tanya Dorff, MD

PATIENT ADVOCATE

Lee Moultrie

BIOSTATISTICIANS

Cathy Tangen, DrPH

Sam Callis, MS

S2210: A Phase II Study of Neoadjuvant Carboplatin for Localized, High-Risk Prostate Cancer with Germline BRCA1/2 Mutations

AGENDA

- Study background and rationale
- Review of protocol and trial workflow
- Patient advocate on genetic testing experience
- Review of first patient experience
- Genetic screening workflows, logistics, helpful resources